Ascent Industries Reports Fourth Quarter and Full Year 2023 Results
Eliminated All Outstanding Debt with Cash Proceeds from the Sale of
New Leadership Focused on Accelerating Profitable Growth and Maximizing Value
Fourth Quarter 2023 Summary 1 |
|||
(in millions, except per share and margin) |
Q4 2023 |
Q4 2022 |
Change |
|
|
|
(23.9)% |
Gross Profit |
|
|
(143.9)% |
Gross Profit Margin |
(5.2)% |
9.0% |
(1,420)bps |
Net (Loss) Income |
|
|
(267.4)% |
Diluted (Loss) Earnings per Share |
|
|
(269.8)% |
Adjusted EBITDA |
|
|
(460.5)% |
Adjusted EBITDA Margin |
(14.4)% |
3.0% |
(1,740)bps |
Full Year 2023 Summary 1 |
|||
(in millions, except per share and margin) |
2023 |
2022 |
Change |
|
|
|
(26.3)% |
Gross Profit |
|
|
(96.5)% |
Gross Profit Margin |
0.8% |
16.5% |
(1,570)bps |
Net (Loss) Income |
|
|
(294.3)% |
Diluted (Loss) Earnings per share |
|
|
(299.4)% |
Adjusted EBITDA |
|
|
(162.3)% |
Adjusted EBITDA Margin |
(8.2)% |
9.8% |
(1,800)bps |
____________________________ | ||
1 |
On |
|
Management Commentary
“The Ascent team made notable progress towards our long-term strategic goals in 2023, despite continued market headwinds,” said Ascent CEO
“We moved into 2024 with a healthy financial position and a commitment to driving sustainable earnings-growth across the enterprise. This commitment is underscored by purposeful initiatives to recapitalize talent and capabilities, aimed to maximize the value derived from the unique strengths within our tubular segment while simultaneously investing in the growth potential of the specialty chemicals segment. We believe our newly-assembled management team has already begun to make progress towards our long-term goals focused on creating durable shareholder value.”
Fourth Quarter 2023 Financial Results
Net sales from continuing operations were
Gross profit from continuing operations was
Net loss from continuing operations was
Adjusted EBITDA was
Full Year 2023 Financial Results
Net sales from continuing operations were
Gross profit from continuing operations was
Net loss from continuing operations was
Adjusted EBITDA was
Segment Results
Ascent Chemicals
– net sales in the fourth quarter of 2023 were
Net sales in 2023 were
Ascent Tubular
– net sales from continuing operations in the fourth quarter of 2023 were
Net sales from continuing operations in 2023 was
Liquidity
During the fourth quarter of 2023, Ascent announced the sale of substantially all the assets of
For the year ended
Conference Call
Ascent will conduct a conference call today at
Ascent management will host the conference call, followed by a question and answer period.
Date:
Time:
Live Call Registration Link: Here
Webcast Registration Link: Here
To access the call by phone, please register via the live call registration link above or here and you will be provided with dial-in instructions and details. If you have any difficulty connecting with the conference call, please contact
The conference call will also be broadcast live and available for replay via the webcast registration link above or here. The webcast will be archived for one year in the investor relations section of the Company’s website at www.ascentco.com.
About
Forward-Looking Statements
This press release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements and to review the risks as set forth in more detail in Ascent Industries Co.’s
Non-GAAP Financial Information
Financial statement information included in this earnings release includes non-GAAP (Generally Accepted Accounting Principles) measures and should be read along with the accompanying tables which provide a reconciliation of non-GAAP measures to GAAP measures.
Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, , shelf registration costs, loss on extinguishment of debt, earn-out adjustments, , retention costs and restructuring & severance costs from net income.
Management believes that these non-GAAP measures are useful because they are key measures used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions as well as allow readers to compare the financial results between periods. Non-GAAP measures should not be considered as an alternative to any measure of performance or financial condition as promulgated under GAAP, and investors should consider the Company's performance and financial condition as reported under GAAP and all other relevant information when assessing the performance or financial condition of the Company. Non-GAAP measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results or financial condition as reported under GAAP.
|
|||||||
Condensed Consolidated Balance Sheets |
|||||||
(in thousands, except par value and share data) |
|||||||
|
|
|
|
||||
|
|
|
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,851 |
|
|
$ |
1,440 |
|
Accounts receivable, net of allowance for credit losses of |
|
26,604 |
|
|
|
33,202 |
|
Inventories |
|
52,306 |
|
|
|
67,671 |
|
Prepaid expenses and other current assets |
|
4,879 |
|
|
|
7,770 |
|
Assets held for sale |
|
2,912 |
|
|
|
380 |
|
Current assets of discontinued operations |
|
861 |
|
|
|
59,912 |
|
Total current assets |
|
89,413 |
|
|
|
170,375 |
|
Property, plant and equipment, net |
|
29,755 |
|
|
|
35,534 |
|
Right-of-use assets, operating leases, net |
|
27,784 |
|
|
|
29,142 |
|
|
|
— |
|
|
|
11,389 |
|
Intangible assets, net |
|
8,496 |
|
|
|
10,001 |
|
Deferred income taxes |
|
5,808 |
|
|
|
1,353 |
|
Deferred charges, net |
|
104 |
|
|
|
203 |
|
Other non-current assets, net |
|
1,935 |
|
|
|
1,862 |
|
Long-term assets of discontinued operations |
|
— |
|
|
|
9,184 |
|
Total assets |
$ |
163,295 |
|
|
$ |
269,043 |
|
|
|
|
|
||||
Liabilities and Shareholders' Equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
16,416 |
|
|
$ |
14,114 |
|
Accrued expenses and other current liabilities |
|
5,108 |
|
|
|
5,509 |
|
Current portion of note payable |
|
360 |
|
|
|
387 |
|
Current portion of long-term debt |
|
— |
|
|
|
2,464 |
|
Current portion of operating lease liabilities |
|
1,140 |
|
|
|
1,015 |
|
Current portion of finance lease liabilities |
|
292 |
|
|
|
280 |
|
Current liabilities of discontinued operations |
|
1,473 |
|
|
|
9,709 |
|
Total current liabilities |
|
24,789 |
|
|
|
33,478 |
|
Long-term debt |
|
— |
|
|
|
69,085 |
|
Long-term portion of operating lease liabilities |
|
29,729 |
|
|
|
30,869 |
|
Long-term portion of finance lease liabilities |
|
1,307 |
|
|
|
1,242 |
|
Other long-term liabilities |
|
60 |
|
|
|
68 |
|
Long-term liabilities of discontinued operations |
|
— |
|
|
|
42 |
|
Total non-current liabilities |
|
31,096 |
|
|
|
101,306 |
|
Total liabilities |
$ |
55,885 |
|
|
$ |
134,784 |
|
|
|
|
|
||||
Commitments and contingencies |
|
|
|
||||
|
|
|
|
||||
Shareholders' equity: |
|
|
|
||||
Common stock, par value |
$ |
11,085 |
|
|
$ |
11,085 |
|
Capital in excess of par value |
|
47,333 |
|
|
|
47,021 |
|
Retained earnings |
|
58,517 |
|
|
|
85,146 |
|
|
|
116,935 |
|
|
|
143,252 |
|
Less: cost of common stock in treasury - 990,282 and 924,504 shares, respectively |
|
(9,525 |
) |
|
|
(8,993 |
) |
Total shareholders' equity |
|
107,410 |
|
|
|
134,259 |
|
Total liabilities and shareholders' equity |
$ |
163,295 |
|
|
$ |
269,043 |
|
Note: The condensed consolidated balance sheets at |
|||||||
|
|||||||||||||||
Condensed Consolidated Statements of Income (Loss) - Comparative Analysis (Unaudited) |
|||||||||||||||
($ in thousands, except per share data) |
|||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Net sales |
|
|
|
|
|
|
|
||||||||
Tubular Products |
$ |
22,765 |
|
|
$ |
30,697 |
|
|
$ |
109,513 |
|
|
$ |
154,040 |
|
Specialty Chemicals |
|
18,451 |
|
|
|
23,473 |
|
|
|
83,616 |
|
|
|
107,542 |
|
All Other |
|
— |
|
|
|
10 |
|
|
|
50 |
|
|
|
411 |
|
|
|
41,216 |
|
|
|
54,180 |
|
|
|
193,179 |
|
|
|
261,993 |
|
Operating income (loss) from continuing operations |
|
|
|
|
|
|
|||||||||
Tubular Products |
|
(3,995 |
) |
|
|
1,232 |
|
|
|
(11,210 |
) |
|
|
22,182 |
|
Specialty Chemicals |
|
(1,623 |
) |
|
|
860 |
|
|
|
(12,558 |
) |
|
|
6,971 |
|
All Other |
|
(116 |
) |
|
|
(175 |
) |
|
|
(801 |
) |
|
|
(508 |
) |
|
|
|
|
|
|
|
|
||||||||
Corporate |
|
|
|
|
|
|
|
||||||||
Unallocated corporate expenses |
|
(2,704 |
) |
|
|
(2,761 |
) |
|
|
(12,018 |
) |
|
|
(12,997 |
) |
Acquisition costs and other |
|
(569 |
) |
|
|
(266 |
) |
|
|
(843 |
) |
|
|
(1,105 |
) |
Total Corporate |
|
(3,273 |
) |
|
|
(3,027 |
) |
|
|
(12,861 |
) |
|
|
(14,102 |
) |
Operating (loss) income |
|
(9,007 |
) |
|
|
(1,110 |
) |
|
|
(37,430 |
) |
|
|
14,543 |
|
Interest expense |
|
1,021 |
|
|
|
1,104 |
|
|
|
4,238 |
|
|
|
2,742 |
|
Other, net |
|
(249 |
) |
|
|
(34 |
) |
|
|
(593 |
) |
|
|
(209 |
) |
(Loss) income from continuing operations before income taxes |
|
(9,779 |
) |
|
|
(2,180 |
) |
|
|
(41,075 |
) |
|
|
12,010 |
|
Income tax benefit |
|
(2,244 |
) |
|
|
(6,681 |
) |
|
|
(6,924 |
) |
|
|
(5,568 |
) |
(Loss) income from continuing operations |
|
(7,535 |
) |
|
|
4,501 |
|
|
|
(34,151 |
) |
|
|
17,578 |
|
Income (loss) from discontinued operations, net of tax |
|
18,674 |
|
|
|
(4,374 |
) |
|
|
7,522 |
|
|
|
4,488 |
|
Net income (loss) |
$ |
11,139 |
|
|
$ |
127 |
|
|
$ |
(26,629 |
) |
|
$ |
22,066 |
|
|
|
|
|
|
|
|
|
||||||||
Net (loss) income per common share from continuing operations |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
(0.75 |
) |
|
$ |
0.44 |
|
|
$ |
(3.37 |
) |
|
$ |
1.72 |
|
Diluted |
$ |
(0.73 |
) |
|
$ |
0.43 |
|
|
$ |
(3.37 |
) |
|
$ |
1.69 |
|
|
|
|
|
|
|
|
|
||||||||
Net income (loss) per common share from discontinued operations |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
1.85 |
|
|
$ |
(0.43 |
) |
|
$ |
0.74 |
|
|
$ |
0.44 |
|
Diluted |
$ |
1.80 |
|
|
$ |
(0.42 |
) |
|
$ |
0.74 |
|
|
$ |
0.43 |
|
|
|
|
|
|
|
|
|
||||||||
Net income (loss) per common share |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
1.10 |
|
|
$ |
0.01 |
|
|
$ |
(2.63 |
) |
|
$ |
2.16 |
|
Diluted |
$ |
1.07 |
|
|
$ |
0.01 |
|
|
$ |
(2.63 |
) |
|
$ |
2.12 |
|
|
|
|
|
|
|
|
|
||||||||
Average shares outstanding |
|
|
|
|
|
|
|
||||||||
Basic |
|
10,107 |
|
|
|
10,213 |
|
|
|
10,140 |
|
|
|
10,230 |
|
Diluted |
|
10,374 |
|
|
|
10,416 |
|
|
|
10,140 |
|
|
|
10,410 |
|
|
|
|
|
|
|
|
|
||||||||
Other data: |
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA1 |
$ |
(5,941 |
) |
|
$ |
1,648 |
|
|
$ |
(15,934 |
) |
|
$ |
25,590 |
|
1 |
The term Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, loss on extinguishment of debt, earn-out adjustments, retention costs and restructuring & severance costs from net income. For a reconciliation of this non-GAAP measure to the most comparable GAAP equivalent, refer to the Reconciliation of Net Income (Loss) to Adjusted EBITDA. |
|
|
|||||||
Consolidated Statements of Cash Flows |
|||||||
($ in thousands) |
|||||||
|
Year Ended |
||||||
|
2023 |
|
2022 |
||||
Operating activities |
|
|
|
||||
Net (loss) income |
$ |
(26,629 |
) |
|
$ |
22,066 |
|
Net income from discontinued operations, net of tax |
|
7,522 |
|
|
|
4,488 |
|
Net (loss) income from continuing operations |
|
(34,151 |
) |
|
|
17,578 |
|
Adjustments to reconcile net (loss) income to net cash provided by operating activities: |
|
|
|
||||
Depreciation expense |
|
6,161 |
|
|
|
6,421 |
|
Amortization expense |
|
1,505 |
|
|
|
1,853 |
|
Amortization of debt issuance costs |
|
99 |
|
|
|
99 |
|
|
|
11,389 |
|
|
|
— |
|
Deferred income taxes |
|
(6,924 |
) |
|
|
(5,568 |
) |
Payments of earn-out liabilities in excess of acquisition date fair value |
|
— |
|
|
|
(372 |
) |
Provision for losses on accounts receivable |
|
(180 |
) |
|
|
478 |
|
Provision for losses on inventories |
|
3,318 |
|
|
|
2,615 |
|
Loss (gain) on disposal of property, plant and equipment |
|
246 |
|
|
|
(18 |
) |
Non-cash lease expense |
|
242 |
|
|
|
414 |
|
Issuance of treasury stock for director fees |
|
— |
|
|
|
364 |
|
Stock-based compensation expense |
|
1,023 |
|
|
|
1,355 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
6,778 |
|
|
|
(264 |
) |
Inventories |
|
12,245 |
|
|
|
(13,685 |
) |
Other assets and liabilities |
|
515 |
|
|
|
(211 |
) |
Accounts payable |
|
1,650 |
|
|
|
(6,269 |
) |
Accounts payable - related parties |
|
— |
|
|
|
(2 |
) |
Accrued expenses |
|
(401 |
) |
|
|
(2,127 |
) |
Accrued income taxes |
|
3,129 |
|
|
|
(7,923 |
) |
Net cash provided by (used in) operating activities - continuing operations |
|
6,644 |
|
|
|
(5,262 |
) |
Net cash provided by operating activities - discontinued operations |
|
16,434 |
|
|
|
10,839 |
|
Net cash provided by operating activities |
|
23,078 |
|
|
|
5,577 |
|
Investing activities |
|
|
|
||||
Purchases of property, plant and equipment |
|
(2,885 |
) |
|
|
(3,394 |
) |
Proceeds from disposal of property, plant and equipment |
|
— |
|
|
|
99 |
|
Net cash used in investing activities - continuing operations |
|
(2,885 |
) |
|
|
(3,295 |
) |
Net cash provided by (used in) investing activities - discontinued operations |
|
53,386 |
|
|
|
(1,680 |
) |
Net cash provided by (used in) investing activities |
|
50,501 |
|
|
|
(4,975 |
) |
Financing activities |
|
|
|
||||
Borrowings from long-term debt |
|
256,606 |
|
|
|
443,363 |
|
Proceeds from note payable |
|
900 |
|
|
|
967 |
|
Proceeds from the exercise of stock options |
|
— |
|
|
|
175 |
|
Payments on long-term debt |
|
(328,155 |
) |
|
|
(442,206 |
) |
Payments on note payable |
|
(928 |
) |
|
|
(580 |
) |
Principal payments on finance lease obligations |
|
(305 |
) |
|
|
(266 |
) |
Payments on earn-out liabilities |
|
— |
|
|
|
(484 |
) |
Repurchase of common stock |
|
(1,287 |
) |
|
|
(1,343 |
) |
Net cash used in financing activities - continuing operations |
|
(73,169 |
) |
|
|
(374 |
) |
Net cash used in financing activities - discontinued operations |
|
— |
|
|
|
(808 |
) |
Net cash used in financing activities |
|
(73,169 |
) |
|
|
(1,182 |
) |
Increase (decrease) in cash and cash equivalents |
|
410 |
|
|
|
(580 |
) |
Less: Cash and cash equivalents of discontinued operations |
|
— |
|
|
|
4 |
|
Cash and cash equivalents, beginning of period |
|
1,441 |
|
|
|
2,017 |
|
Cash and cash equivalents, end of period |
$ |
1,851 |
|
|
$ |
1,441 |
|
|
|||||||||||||||
Non-GAAP Financial Measures Reconciliation |
|||||||||||||||
Reconciliation of Net Income (Loss) to Adjusted EBITDA (Unaudited) |
|||||||||||||||
($ in thousands) |
|||||||||||||||
|
|
|
|
|
|
|
|||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
($ in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Consolidated |
|
|
|
|
|
|
|
||||||||
Net (loss) income from continuing operations |
$ |
(7,535 |
) |
|
$ |
4,501 |
|
|
$ |
(34,151 |
) |
|
$ |
17,578 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
1,021 |
|
|
|
1,104 |
|
|
|
4,238 |
|
|
|
2,742 |
|
Income taxes |
|
(2,244 |
) |
|
|
(6,681 |
) |
|
|
(6,924 |
) |
|
|
(5,568 |
) |
Depreciation |
|
1,527 |
|
|
|
1,579 |
|
|
|
6,161 |
|
|
|
6,421 |
|
Amortization |
|
376 |
|
|
|
429 |
|
|
|
1,505 |
|
|
|
1,853 |
|
EBITDA |
|
(6,855 |
) |
|
|
932 |
|
|
|
(29,171 |
) |
|
|
23,026 |
|
Acquisition costs and other |
|
579 |
|
|
|
266 |
|
|
|
856 |
|
|
|
1,104 |
|
Shelf registration costs |
|
— |
|
|
|
12 |
|
|
|
— |
|
|
|
12 |
|
|
|
— |
|
|
|
— |
|
|
|
11,389 |
|
|
|
— |
|
Gain on lease modification |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
Stock-based compensation |
|
224 |
|
|
|
283 |
|
|
|
594 |
|
|
|
962 |
|
Non-cash lease expense |
|
52 |
|
|
|
91 |
|
|
|
242 |
|
|
|
414 |
|
Retention expense |
|
20 |
|
|
|
— |
|
|
|
26 |
|
|
|
— |
|
Restructuring and severance costs |
|
39 |
|
|
|
64 |
|
|
|
130 |
|
|
|
74 |
|
Adjusted EBITDA |
$ |
(5,941 |
) |
|
$ |
1,648 |
|
|
$ |
(15,934 |
) |
|
$ |
25,590 |
|
% sales |
|
(14.4 |
)% |
|
|
3.0 |
% |
|
|
(8.2 |
)% |
|
|
9.8 |
% |
Tubular Products |
|
|
|
|
|
|
|
||||||||
Net (loss) income from continuing operations |
$ |
(3,995 |
) |
|
$ |
1,232 |
|
|
$ |
(11,210 |
) |
|
$ |
22,182 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Depreciation expense |
|
557 |
|
|
|
609 |
|
|
|
2,274 |
|
|
|
2,500 |
|
Amortization expense |
|
217 |
|
|
|
238 |
|
|
|
871 |
|
|
|
951 |
|
EBITDA |
|
(3,221 |
) |
|
|
2,079 |
|
|
|
(8,065 |
) |
|
|
25,633 |
|
Stock-based compensation |
|
74 |
|
|
|
11 |
|
|
|
58 |
|
|
|
46 |
|
Non-cash lease expense |
|
25 |
|
|
|
— |
|
|
|
118 |
|
|
|
— |
|
Retention expense |
|
8 |
|
|
|
— |
|
|
|
8 |
|
|
|
— |
|
Restructuring and severance costs |
|
— |
|
|
|
20 |
|
|
|
84 |
|
|
|
20 |
|
Tubular Products Adjusted EBITDA |
$ |
(3,114 |
) |
|
$ |
2,110 |
|
|
$ |
(7,797 |
) |
|
$ |
25,699 |
|
% segment sales |
|
(13.7 |
)% |
|
|
6.9 |
% |
|
|
(7.1 |
)% |
|
|
16.7 |
% |
|
|
|
|
|
|
|
|
||||||||
Specialty Chemicals |
|
|
|
|
|
|
|
||||||||
Net (loss) income |
$ |
(1,644 |
) |
|
$ |
852 |
|
|
$ |
(12,619 |
) |
|
$ |
6,935 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
22 |
|
|
|
9 |
|
|
|
74 |
|
|
|
36 |
|
Depreciation expense |
|
948 |
|
|
|
949 |
|
|
|
3,798 |
|
|
|
3,846 |
|
Amortization expense |
|
158 |
|
|
|
191 |
|
|
|
634 |
|
|
|
903 |
|
EBITDA |
|
(516 |
) |
|
|
2,001 |
|
|
|
(8,113 |
) |
|
|
11,720 |
|
Acquisition costs and other |
|
10 |
|
|
|
— |
|
|
|
12 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,389 |
|
|
|
— |
|
Stock-based compensation |
|
21 |
|
|
|
12 |
|
|
|
8 |
|
|
|
41 |
|
Non-cash lease expense |
|
19 |
|
|
|
— |
|
|
|
88 |
|
|
|
2 |
|
Restructuring and severance costs |
|
40 |
|
|
|
8 |
|
|
|
40 |
|
|
|
8 |
|
Specialty Chemicals Adjusted EBITDA |
$ |
(426 |
) |
|
$ |
2,021 |
|
|
$ |
3,424 |
|
|
$ |
11,771 |
|
% segment sales |
|
(2.3 |
)% |
|
|
8.6 |
% |
|
|
4.1 |
% |
|
|
10.9 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328924168/en/
Company Contact
Chief Financial Officer
1-630-884-9181
Investor Relations
1-949-574-3860
ACNT@gateway-grp.com
Source: